Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunic Inc (NQ: IMUX )

1.180 +0.080 (+7.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,520,694
Open 1.150
Bid (Size) 1.190 (24)
Ask (Size) 1.210 (7)
Prev. Close 1.100
Today's Range 1.140 - 1.295
52wk Range 0.9700 - 2.110
Shares Outstanding 26,249,439
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga

Performance

YTD
-18.62%
-18.62%
1 Month
-15.11%
-15.11%
3 Month
-18.62%
-18.62%
6 Month
-5.60%
-5.60%
1 Year
+0.85%
+0.85%

More News

Read More
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
Via InvestorPlace
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Via TheNewswire.com
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Via News Direct
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
Via InvestorPlace
Immunic's Earnings Outlook
Via Benzinga
Immunic: Q3 Earnings Insights
Via Benzinga
A Preview Of Immunic's Earnings
Via Benzinga
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Via News Direct
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Via TheNewswire.com
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Via News Direct
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Via TheNewswire.com
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Via News Direct
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Via TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Via News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Via TheNewswire.com
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Immunic Stock?
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Immunic CSO hails "great" progress with MS program
Via News Direct
Immunic CSO hails "great" progress with MS program
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.